...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular cancer therapeutics >Shining the light on aurora-a kinase as a drug target in pancreatic cancer.
【24h】

Shining the light on aurora-a kinase as a drug target in pancreatic cancer.

机译：点亮作为胰腺癌药物靶标的Aurora-a激酶。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We were honored to learn that our article, "The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer" was selected as one of "The Best of MCT-10 Years." The work presented in this paper has led to many studies examining the role of Aurora kinases in cancer and additional trans-lational studies taking new drugs forward into the clinic. For many years, my research group has had an interest in identifying new potential targets for drug discovery and development in adenocarcinomas of the pancreas. Our earlier work from genomic and gene expression studies using pancreatic cancer cell lines and tumor samples taken directly from patients, identified Aurora-2 (also known as Aurora-A), as a gene that was amplified and significantly up-regulated at the mRNA and protein level in pancreatic cancers (1).
机译：我们很高兴得知我们的文章“有丝分裂的丝氨酸苏氨酸激酶Aurora-2是人类胰腺癌药物开发的潜在靶标”被选为“ MCT-10年最佳”之一。本文提出的工作已导致许多研究检查了Aurora激酶在癌症中的作用，并且进行了更多的将新药推向临床的翻译研究。多年来，我的研究小组一直对确定胰腺腺癌中药物发现和开发的新潜在靶标感兴趣。我们使用胰腺癌细胞系和直接从患者身上采集的肿瘤样本进行的基因组和基因表达研究的早期工作，将Aurora-2（也称为Aurora-A）鉴定为一种基因，该基因在mRNA和mRNA处被扩增并显着上调。胰腺癌中的蛋白质水平（1）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号